SLC5A2 and Hepatic fibrosis: The effect of SGLT2 inhibitors on hepatocyte necrosis, inflammation and/or fibrosis is less studied but there are indications that treatment with some SGLT2 inhibitors, such as dapagliflozin [96], canagliflozin [98] and ipragliflozin [102] (but not empagliflozin [104] or ertugliflozin [103]), improves variables of liver fibrosis.